<DOC>
	<DOC>NCT01002105</DOC>
	<brief_summary>This is a study of Baclofen as an add-on to standard treatment for alcohol-dependent patients.</brief_summary>
	<brief_title>Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients</brief_title>
	<detailed_description>Double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations. The percentages of heavy drinking days and abstinent days were the primary outcome measures, and craving; distress and depression levels; self-efficacy; social support from family, friends and significant others; and health-related quality of life (HRQL) were secondary outcomes. Tolerability was also examined.</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>1. ICD10 diagnosis of alcohol dependence (World Health Organization, 1993); 2. Seeking treatment with the aim to stop alcohol consumption; 3. Age ranging from 18 to 60 years; 4. Last alcohol intake reported in the 24 h preceding observation; 5. Presence of a referred family member; 6. Written informed consent provision. . 1. Serious hepatic, kidney, lung, neurological and cardiovascular, diseases); 2. Suicide risk, acute psychosis, severe depression, organic brain syndromes; 3. Dependence on psychoactive substances other than nicotine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Baclofen</keyword>
	<keyword>Alcohol</keyword>
	<keyword>Baclofen as add-on to standard treatment of alcohol</keyword>
</DOC>